Brought to you by:
ESVS publishes 2025 vascular trauma guidelines
The European Society for Vascular Surgery (ESVS) has developed new guidelines for the care of patients with vascular trauma. The 2025 clinical practice guideline document was recently published as an open-access article in press in the European Journal of Vascular…
FDA approves Humacyte’s Symvess for vascular trauma
Humacyte recently shared that the Food and Drug Administration (FDA) has granted a full approval for the Symvess acellular tissue-engineered vessel. A press release notes that Symvess is indicated for use in adults as a vascular conduit for extremity arterial…
SVS Women’s Section delves into vascular trauma treatment intricacies amid ‘paucity of literature’
“Life over limb”—that was one of the key messages to emerge from the VAM 2024 SVS Women’s Section session that placed a lens over vascular trauma treatment. Misty Humphries, MD, associate professor of surgery at University of California Davis in…
Women’s Section to place a lens over vascular trauma
The SVS Women’s Section will host their VAM 2024 session, “Vascular Trauma: What I Need to Know in the Middle of the Night” at 3:30–5 p.m. on Friday (West Building, Level 1, W184a). The session will feature talks about different…
Pediatric vascular trauma: ‘Collaboration really matters in this space’
The focus of yesterday’s American Pediatric Surgical Association (APSA)-SVS task force’s spring quarterly interest group meeting at VAM 2024 was the “incredibly crucial” topic of pediatric trauma, as described by co-moderator John White, MD. Various speakers shared a series of…
Pediatric vascular care in focus: Raising awareness of supportive care processes
In 2021, the Society for Vascular Surgery (SVS) and the American Pediatric Surgical Association (APSA) established a task force dedicated to optimizing pediatric vascular care through a multidisciplinary educational approach. The task force created a Pediatric Vascular Surgery Interest Group,…
Humacyte submits Biologics License Application to FDA seeking approval of Human Acellular Vessel
Humacyte today announced that it has submitted a Biologics License Application (BLA) to the Food and Drug Administration (FDA) seeking approval of the Human Acellular Vessel (HAV) in urgent arterial repair following extremity vascular trauma when synthetic graft is not…
SVS webinar covers insights learned from experiences of mass-casualty disasters
A mass shooting in Las Vegas. A bombing at the finish line of the Boston Marathon. A shooting at a Fourth of July parade. Healthcare workers may not be on the actual front line of disasters, but they’re definitely in…
MVSS 2023: Human Acellular Vessel proves ‘safe, effective bypass conduit’ in complex CLTI cohort
An investigator-sponsored clinical study conducted at the Mayo Clinic in Rochester, Minnesota, of the investigational Human Acellular Vessel (HAV) in patients with chronic limb-threatening ischemia (CLTI) was presented at the Midwestern Vascular Surgical Society (MVSS) annual meeting in Minneapolis, Minnesota…
Humacyte announces positive top line results from Phase 2/3 trial of Human Acellular Vessel in treatment of patients with vascular trauma
Humacyte has announced positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair. A press release reports that the single-arm clinical trial was a success and showed that the HAV…